eligibility_summary
Eligible: Adults 18–80 with path‑confirmed CRC liver mets, GCC IHC ≥1+ in >50% tumor, ≥1 measurable lesion, refractory/intolerant after ≥3rd‑line, OS ≥90 d, adequate marrow/liver/renal, INR per protocol, LVEF >50%, no bleeding disorder, negative pregnancy test/contraception, consent. Exclude: pregnancy, recent therapy/trial, major CV/thromboembolism/QTc>480, active infections (HIV/syphilis/HBV/HCV), uncontrolled effusions, severe drug allergy, active autoimmune, CNS mets, ILD/severe lung dz, unresolved AEs, substance abuse, or other unsafe conditions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: REVO-UWD-01, a universal (allogeneic) CAR-T cell therapy (biologic, cellular gene therapy) made from healthy-donor T cells. Mechanism: T cells are engineered with a CAR whose scFv binds guanylyl cyclase C (GCC), GCC engagement activates CAR signaling, driving T-cell cytotoxicity and cytokine release to kill GCC+ tumor cells. Patients receive lymphodepleting chemotherapy (fludarabine/cyclophosphamide) before infusion to promote engraftment. Targets: GCC-expressing metastatic colorectal cancer cells, pathway focus: GCC surface antigen and CAR-T activation pathways.